NAFDAC denies banning Amoxicillin

The Nationwide Company for Meals and Drug Administration and Management (NAFDAC) has denied claims circulating on social media that Amoxicillin has been secretly banned in Nigeria, describing the stories as false and deceptive.

The clarification was issued in an announcement posted on NAFDAC’s official X (previously Twitter) account on Monday, February 9, 2026.

In response to the company, whereas it routinely points focused security alerts and recollects for particular substandard or affected batches of medicines, there is no such thing as a blanket ban on the antibiotic in Nigeria.

The denial follows the circulation of a viral video alleging that NAFDAC had quietly prohibited the sale and use of Amoxicillin nationwide. NAFDAC stated the declare misrepresents its regulatory processes and dangers inflicting pointless panic amongst healthcare suppliers and most of the people.

What they’re saying

NAFDAC stated it stays dedicated to transparency and all the time communicates regulatory actions by official and verifiable channels. The company pressured that any motion affecting medicines in circulation is publicly introduced and clearly outlined.

• “The Nationwide Company for Meals and Drug Administration and Management (NAFDAC) needs to debunk a video circulating on social media alleging that the company has secretly banned the sale and use of Amoxicillin in Nigeria. This declare is fake and devoid of any factual foundation.”
• “NAFDAC has not banned Amoxicillin in Nigeria, both secretly or overtly. As a accountable regulatory authority, the Company publicly notifies Nigerians of any regulatory actions by official channels.”
• “NAFDAC alerts the general public by its Remembers, Security Alerts, Blacklists, and different security notices of any substandard, falsified, or affected merchandise requiring regulatory motion.”

The company reiterated that regulatory transparency is central to its mandate and urged the general public to ignore claims not backed by official statements.

Extra perception

NAFDAC defined that its security communications are product-specific and designed to guard public well being with out disrupting entry to important medicines. These alerts clearly determine the affected merchandise and the actions required by stakeholders.

Security communications specify product names, batch numbers, producers, and corrective measures.

The knowledge supplied helps therapy and diagnostic choices by healthcare professionals.

Blacklisting, the place utilized, targets particular corporations resulting from security issues, regulatory violations, or unethical practices.

• “In latest months, NAFDAC issued focused security alerts on sure manufacturers and batches of Amoxicillin,” the company stated.

It cited Public Alert No. 24/2025 issued in August 2025 on the recall of Amoxivue (Amoxicillin) 500mg capsules resulting from low Energetic Pharmaceutical Ingredient (API) content material. In October 2025, Public Alert No. 34/2025 addressed substandard batches of Astamocil and Astamentin suspensions, whereas Public Alert No. 35/2025 lined substandard batches of Annmox and Jawamox suspensions.

NAFDAC pressured that these actions have been restricted to recognized merchandise and don’t quantity to a ban on Amoxicillin.

Why it issues

NAFDAC’s clarification is vital as a result of Amoxicillin is a extensively used and important antibiotic for treating a spread of bacterial infections, together with pneumonia, bronchitis, and ear infections.

Misinformation suggesting a nationwide ban may disrupt therapy, encourage panic shopping for, or lead sufferers to desert prescribed medicine.

• False claims can undermine public belief in regulatory establishments.
• Panic or confusion could lead to inappropriate self-medication or therapy delays.
• Clear regulatory communication helps guarantee continued entry to secure and efficient medicines.

Moderately than imposing blanket bans, NAFDAC’s strategy of concentrating on substandard batches ensures that solely high quality medicines stay in circulation, defending sufferers whereas sustaining entry to important medication. The company suggested Nigerians to depend on verified data from its official platforms.

What it’s best to know

NAFDAC has, previously, taken agency motion towards unsafe pharmaceutical merchandise to safeguard public well being. In September 2025, the company introduced the rapid withdrawal, suspension, and cancellation of 101 pharmaceutical merchandise from the Nigerian market.

• The affected merchandise have been barred from manufacture, importation, exportation, distribution, commercial, sale, and use in Nigeria.
• The listing spanned antimalarials, cardiovascular medication, insulin, growth-hormone injectables, diabetes medicines, inhalers, and eye drops.
• Broadly used medication on the listing included Abacavir tablets, Amaryl tablets, Aprovasc tablets, Artemether/Lumefantrine mixtures, ASAQ formulations, and Amlodipine.

NAFDAC stated these actions mirror its ongoing efforts to make sure that medicines obtainable in Nigeria meet required security, high quality, and efficacy requirements.